Boehringer Ingelheim
My giotrif logo

Afatinib
Afatinib

Read more

Video: Uncommon EGFR pooled analysis in 693 patients

16/04/2024  |  Author: Boehringer Ingelheim

Document ID: PC-MY-101511

Efficacy

MYGIO2022COM||GIOTRIF® provides ≥3 years long-term response even with dose modification
MYBIONEGIO2022||South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
SEREAL||First-line GIOTRIF® data in over 30 real-world studies to-date
GIOTRIF® safety and effectiveness in the real world
Real-world evidence: GIOTRIF® in Japan
MYSEREAL||Real-world evidence: GIOTRIF® in Taiwan
Video: Uncommon EGFR pooled analysis in 693 patients
Real-world evidence: GIOTRIF® in South Korea
SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
SEREAL||GIOTRIF® RWE in patients with brain metastases
SEREAL||Impact of GIOTRIF® in delaying CNS progression
SEREAL||GIOTRIF® RWE in Taiwan
SEREAL||GIOTRIF® efficacy in the real-world
SEREAL||GIOTRIF® in LUX-Lung 7
MYGIO2022COM||GIOTRIF® in elderly
MYBIONEGIO2022||GIOTRIF® in uncommon EGFR mutations
RWDRI||GIOTRIF® in Uncommon Mutation - A database analysis of >1000 NSCLC Patients

RELATED CONTENT